Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.Aurinia Pharmaceuticals - $AUPHThe FDA approved Aurinia Pharmaceuticals Inc's NDA for voclosporin as a treatment option for lupus nephritis, an autoimmune disorder that leads to inflammation of kidney. The decision was expected by Friday, Jan. 22.Our Take: FDA approves their Lupus Drug! Congrats to all the longs! Approval was almost a sure thing, so be careful of the trading reaction to this news next week.Exelixis combo approval came a month ahead of PDUFA, says Piper SandlerPiper Sandler analyst Edward Tenthoff reiterates his Overweight rating and $33 target on Exelixis shares after the FDA approved Cabometyx in combination with Opdivo for first-line renal cell carcinoma, noting that the approval came a month ahead of the February 20 PDUFA date the agency had assigned. Tenthoff, who forecasts Cabometyx sales to re-accelerate to $980M in 2021 and $1.35B in 2022, next looks toward continued progress in label expansion in radioiodine-refractory differentiated thyroid cancer, metastatic castration-resistant prostate cancer, or mCRPC, and non-small cell lung cancer, or NSCLC, he tells investors.Our Take: Good news for EXEL. This remains on our favorites list and should see some trading action on Monday. A good tradable biotech stock and good as a longer term healthcare holding. $EXEL, Exelixis, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .